UK pharma terms — explained simply
Plain-English definitions of the regulatory, pharmacovigilance and clinical-development terms healthcare professionals encounter on the way into pharma. Curated by Dorothy Ogwuru and the PharmaLink Academy team.
Regulatory
Terms healthcare professionals encounter when they first read pharma job descriptions.
MAA Marketing Authorisation Application
The formal regulatory submission a pharmaceutical company makes to a regulator (such as the MHRA in the UK or EMA in Europe) to obtain approval to market a new medicine. Regulatory medical writers prepare large parts of the MAA dossier.
MHRA Medicines and Healthcare products Regulatory Agency
The UK's medicines regulator. Reviews and approves new medicines for the UK market, oversees post-market drug safety, and inspects pharmacovigilance and manufacturing systems.
EMA European Medicines Agency
The EU regulator responsible for evaluating and supervising medicines for human and veterinary use across European member states.
FDA Food and Drug Administration
The US medicines regulator. Many UK-based regulatory medical writing roles involve preparing dossiers for FDA submission as well as MHRA and EMA.
ICH International Council for Harmonisation
The international body that publishes harmonised technical guidelines for medicine development. ICH guidelines (E3, E6, E14, etc.) define the structure of clinical study reports, GCP, and many other pharma documents.
GCP Good Clinical Practice
The international ethical and scientific quality standard for designing, conducting and reporting clinical trials. GCP training is a baseline expectation for almost every pharma role.
Pharmacovigilance
The drug safety side of pharma — also called PV or post-market surveillance.
Pharmacovigilance PV
The science and practice of monitoring the safety of medicines after they reach the market. Covers detection, assessment, understanding and prevention of adverse effects. The pharmaceutical industry's largest entry-level career pathway for healthcare professionals.
Read the full UK pharmacovigilance career guide →ICSR Individual Case Safety Report
The fundamental unit of pharmacovigilance work. A structured safety report describing a single adverse event in a single patient. Drug Safety Associates spend most of their first months processing ICSRs.
MedDRA Medical Dictionary for Regulatory Activities
The international standardised medical terminology used to code adverse events in ICSRs. MedDRA proficiency is one of the first technical skills a Drug Safety Associate must develop.
Signal management
The process of detecting patterns in safety data that might indicate a previously unknown adverse effect of a medicine, then validating, prioritising and assessing those patterns. Tier 2 PV work in the PharmaLink Academy programme structure.
PSUR Periodic Safety Update Report
A periodic regulatory document summarising the worldwide safety experience of a medicine over a defined time interval. Authoring PSURs is a core senior pharmacovigilance writing task.
DSUR Development Safety Update Report
An annual safety report for medicines still in clinical development, summarising safety findings from ongoing trials. Authored by the regulatory writing or pharmacovigilance teams.
PBRER Periodic Benefit-Risk Evaluation Report
The ICH-harmonised successor to the PSUR for marketed medicines, balancing benefit and risk over a defined interval. Senior PV writing deliverable.
Drug Safety Associate
The most common entry-level role into pharmacovigilance. Day-to-day work centres on ICSR processing, MedDRA coding, and case follow-up. Typical UK salary range: £28K–£42K starting.
Explore PV Tier 1 programme →Clinical development
The clinical-trial side of pharma where regulatory medical writers spend most of their time.
CRO Contract Research Organisation
A company that runs clinical trials and pharmacovigilance services on behalf of pharmaceutical sponsors. Many UK pharma jobs are based in CROs (IQVIA, Parexel, Labcorp, ICON, etc.) rather than pharma manufacturers directly.
Sponsor
The pharmaceutical company funding and ultimately responsible for a clinical trial or marketed medicine. Sponsors and CROs are the two main employer categories for pharma careers.
Phase I / II / III / IV
The four phases of clinical trials. Phase I (safety in healthy volunteers), Phase II (small efficacy trials), Phase III (large pivotal trials for approval), Phase IV (post-marketing studies). Different writing deliverables map to different phases.
Document types
The deliverables a regulatory medical writer actually produces.
CSR Clinical Study Report
The full ICH E3-format report of a clinical trial. Often 200–500 pages. The flagship deliverable for most regulatory medical writers and a major component of a marketing authorisation application.
IB Investigator's Brochure
The compendium of all available clinical and non-clinical data on an investigational medicine, given to clinical trial investigators. Updated annually and authored by regulatory medical writers.
Briefing book
A document prepared in advance of a regulatory meeting (e.g. with the FDA or MHRA) summarising the questions a sponsor wants to ask and the supporting evidence. High-impact regulatory writing.
Protocol
The document that defines how a clinical trial will be conducted — patient population, treatments, endpoints, statistical plan. Protocol writing is a senior regulatory writing skill.
Systems & tools
The actual software pharma uses every day — and PharmaLink's training analogues.
Argus Safety
The most common pharmacovigilance case-management system in industry, used by most major pharma companies and CROs to process ICSRs.
ARISg
An alternative pharmacovigilance case-management system to Argus. Many CROs use either ARISg or Argus depending on the sponsor.
VIGILANT™
PharmaLink Academy's proprietary safety database — a live pharmacovigilance environment that mirrors the industry case-management systems Drug Safety Associates use every day. Cohort learners practise real ICSR processing, MedDRA coding and signal workflows in VIGILANT™ rather than generic e-learning, so they walk into PV interviews already fluent in the system.
See VIGILANT™ in the Pharmacovigilance Programme →FORGE™
PharmaLink Academy's live meeting and scenario simulator paired with the Regulatory Medical Writing Programme. Cohort members practise pharma meetings, stakeholder queries and parallel deliverables in a realistic environment, so interview-readiness includes meeting-room presence, not just document drafting.
Explore FORGE™ in the RMW Programme →CTD Common Technical Document
The internationally harmonised structure for organising regulatory submissions to MHRA, EMA, FDA and other major regulators. Modules 1–5 cover everything from administrative information to clinical study reports.
Want to learn what these terms actually feel like in practice?
The PharmaLink Academy live cohorts are built around the systems and document types defined here — taught by senior pharma instructors, not academics.
Explore the programmes